Cardiovascular Risk in Patients with Psoriatic Arthritis

Tracy Y Zhu,Edmund K Li,Lai-Shan Tam

doi:10.1155/2012/714321

Tracy Y Zhu, Edmund K Li + Show 1 more

Open Access

https://doi.org/10.1155/2012/714321

Copy DOI

Abstract

Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. In addition to skin and joint involvement, there is increasing evidence suggesting that patients with PsA also have an increase in risk of clinical and subclinical cardiovascular diseases, mostly due to accelerating atherosclerosis. Both conventional and nonconventional cardiovascular risk factors contribute to the increased cardiovascular risk in PsA. Chronic inflammation plays a pivotal role in the pathogenesis of atherosclerosis in PsA, acting independently and/or synergistically with the conventional risk factors. In this paper, we discuss the current literature indicating that patients with PsA are at risk of cardiovascular diseases.

Highlights

Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis associated with psoriasis
The objective of this paper is to provide an overview of the current literature indicating that patients with PsA are at risk of cardiovascular disease (CVD)
The study by Gonzalez-Juanatey et al did not found significant subclinical cardiac abnormalities in 50 patients with PsA without clinically evident CVD or atherosclerosis risk factors when compared with 50 matched healthy controls [38]

Summary

Introduction

Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis associated with psoriasis. Patients with PsA have heterogeneous clinical presentations with diverse articular and dermatological features as well as varied disease course and outcomes. In addition to skin and musculoskeletal involvement, there is increasing evidence suggesting that patients with PsA have an increase in risk of cardiovascular disease (CVD) [5,6,7]. The objective of this paper is to provide an overview of the current literature indicating that patients with PsA are at risk of CVD. A better knowledge of the association between PsA and cardiovascular comorbidities can help in early management and modification of risk factors, minimize the impact of the cardiovascular comorbidities, and improve patients’ long-term outcome

Objectives

Results

Conclusion